eng Oriental Scientific Publishing Company Biosciences Biotechnology Research Asia 0973-1245 2025-12-30 22 4 1695 1711 10.13005/bbra/3470 57087 article Manoj Joshi 1 Chetana Suvalka 1 Department of Zoology, Sangam University, Bhilwara, Rajasthan, India The emergence and spread of drug resistance in Plasmodium falciparum, the parasite causing the most severe form of malaria is a major threat to malaria control and elimination program around the globe. With Plasmodium falciparum having evolved widespread resistance against a number of previously widely used drugs, currently artemisinine and its derivatives are the cornerstones of first line treatment of uncomplicated malaria. Growing incidences failure reflects artemisinine resistance. Pharmacology approach in this study is being used against AMA1 protein which can be used as major target for drug due to its participation in erythrocytic infection stage. This protein is conserved in all plasmodium  species. The AMA1-PLAF8 structure is modelled through homology modelling method and virtual screening against Catharanthus roseus fraction is carries out using Maetrso. Secologanin,Vindoline,tabersonine,Vincristine,Serpentine, Ajmalicine,Catharanthine and catechol were taken for screening. Secaloganine showed the best binding results with lowest binding energy (-7.815 Kcal/mol) and shortest bond length i.e. 1.80881 Ǻ. This virtual screening investigation suggests that Secaloganin can be repurposed for malaria control and prevention. https://www.biotech-asia.org/vol22no4/in-silico-design-of-antimalarial-drug-from-catharanthus-roseus-g-donalkaloid-molecules-against-ama1-protein/ Apical Membrane Antigen 1 (AMA 1); Artemesinine resistance; Malaria; Molecular docking; XP Gscore